[Congressional Record Index (1998)]
[From the U.S. Government Publishing Office, www.gpo.gov]
PHARMACEUTICALS related term(s) Drugs
Articles and editorials
Medications From Mexico, S7261 [26JN]
Bills and resolutions
Controlled Substances Act: civil liability for illegal
manufacturers and distributors of controlled substances, (see
H.R. 4204), H5492 [14JY]
DEA: assessment of fines on pharmacies for record keeping
violations, (see S. 2600), S12164 [9OC]
Dept. of HHS: ensure individuals who undertake federally funded
research and development of drugs enter into pricing agreements,
(see H.R. 3758), H2605 [29AP]
Diseases: Medicare coverage and research funding for amyotrophic
lateral sclerosis, (see S. 2265), S7574 [7JY]
Drugs: distribution chain of prescription drugs, (see H.R. 4024),
H4325 [9JN]
------ limit amount of controlled substances allowed to be brought
into the U.S. from Mexico and Canada, (see S. 2242), S7255
[26JN]
------ provided incentives for the development of medications to
treat drug addiction, (see S. 2015), S3919 [30AP]
------ rescheduling of certain drugs which pose a danger to public
safety, (see S. 2014), S3919 [30AP]
------ rescheduling of flunitrazepam into schedule I of the
Controlled Substances Act, (see H.R. 3093), H62 [27JA]
------ restrict disclosure of prescription information by pharmacy
owners, pharmacists, and other pharmacy employees, (see H.R.
3756), H2605 [29AP]
------ support existing Federal legal process for determining safety
and efficacy of using marijuana and other drugs for medicinal
purposes, (see S.J. Res. 56), S10657 [21SE], (see S.J. Res. 57),
S10657 [21SE]
------ use of marijuana for medicinal purposes, (see H.J. Res. 117),
H2706 [30AP]
FDA: establish therapeutic equivalence requirements for generic
drugs, (see H.R. 4849), H11042 [16OC]
------ require notification of recalls of drugs and devices, (see S.
1767), S1990 [16MR], (see H.R. 3462), H1158 [12MR]
Foreign trade: limit controlled substances from Mexico, (see H.R.
3633), H2052 [1AP]
Insurance: coverage of prescription drugs, (see H.R. 4559), H7690
[14SE]
Medicare: clarify non-preemption of State prescription drug benefit
laws relative to Medicare+Choice plans, (see H.R. 4648), H9084
[26SE]
------ coverage of outpatient prescription drugs and home infusion
drug therapy, (see H.R. 4753), H10076 [8OC]
------ ensure access to comparable prescription drug coverage in
Medigap policies relative to termination of Medicare+Choice
plans, (see H.R. 4862), H11695 [20OC]
------ exempt licensed pharmacists from surety bond requirements for
suppliers of durable medical equipment, (see S. 1680), S1003
[25FE], (see H.R. 3284), H676 [26FE]
------ limit payments for drugs or biological products, (see H.R.
3139), H240 [3FE]
------ reductions in prescription drug prices, (see H.R. 4627),
H8931 [25SE], (see H.R. 4646), H9083 [26SE], (see H.R. 4794),
H10513 [10OC]
NIH: establish National Center for Complementary and Alternative
Medicine, (see S. 2420), S9556 [31JY]
Prescription Drug Price Monitoring Commission: establish, (see H.R.
3925), H3742 [21MY]
Tariff: anti-cancer drugs, (see H.R. 3386, S. 1936), S3217 [3AP],
(see S. 1937), S3218 [3AP], (see S. 1938), S3218 [3AP], (see S.
1939), S3218 [3AP], (see S. 1940), S3218 [3AP], (see S. 1941),
S3218 [3AP], (see S. 1944), S3218 [3AP], (see S. 1945), S3218
[3AP], H903 [5MR], (see H.R. 3387), H903 [5MR]
------ anti-HIV and anti-AIDS drug production, (see H.R. 3328, S.
1810), S2424 [23MR], H850 [4MR], (see H.R. 3385), H903 [5MR]
------ HIV antiviral drug production, (see H.R. 3384, S. 1946),
S3218 [3AP], (see S. 1947), S3218 [3AP], (see S. 1948), S3218
[3AP], (see S. 1949), S3218 [3AP], (see S. 1950), S3218 [3AP],
(see S. 1951), S3218 [3AP], (see S. 1952), S3218 [3AP], (see S.
1953), S3218 [3AP], (see S. 1954), S3218 [3AP], (see S. 1955),
S3218 [3AP], (see S. 1956), S3218 [3AP], (see S. 2399), S9556
[31JY], H903 [5MR], (see H.R. 3388), H903 [5MR], (see H.R.
3389), H903 [5MR], (see H.R. 3390), H903 [5MR], (see H.R. 3391),
H903 [5MR], (see H.R. 3392), H903 [5MR], (see H.R. 3393), H903
[5MR], (see H.R. 3394), H903 [5MR], (see H.R. 3428), H1020
[10MR], (see H.R. 3429), H1021 [10MR], (see H.R. 3477), H1236
[17MR], (see H.R. 4190), H5404 [25JN], (see H.R. 4191), H5404
[25JN]
------ HIV protease inhibitor production, (see S. 1942), S3218
[3AP], (see S. 1943), S3218 [3AP]
Taxation: treatment of excise tax on vaccines, (see S. 2118), S5434
[22MY]
WHO: encourage the U.S. becoming a signatory to the Guidelines for
Drug Donations, (see H. Con. Res. 225), H677 [26FE]
Excerpts
Next Ten Years of Health Spending--What Does the Future Hold?, E2101
[12OC]
Letters
Controlled Substances Trafficking Prohibition Act: Representative
Bliley, Committee on Commerce (House), H6903 [3AU]
----- Representative Hyde, Committee on the Judiciary (House), H6903
[3AU]
Human Cloning Prohibition Act: Alan F. Holmer, Pharmaceutical
Research and Manufacturers of America, S578 [10FE]
------ William L. Respess, Ligand Pharmaceuticals (company), S579
[10FE], S580 [10FE]
Licensed pharmacists' exemption from surety bond requirements for
suppliers of durable medical equipment under Medicare: Galen
Jordre, North Dakota Pharmaceutical Association, S1013 [25FE]
----- John A. Gans, American Pharmaceutical Association, S1013
[25FE]
----- John M. Rector, National Community Pharmacists Association,
S1013 [25FE]
Prescription drug prices, E138 [11FE]
Support existing Federal legal process for determining safety and
efficacy of using marijuana and other drugs for medicinal
purposes: Barry R. McCaffrey, Office of National Drug Control
Policy, S10665 [21SE]
Proposals
Support existing Federal legal process for determining safety and
efficacy of using marijuana and other drugs for medicinal
purposes: Committee on the Judiciary (House), H7725 [15SE]
Remarks in House
Cleveland, OH: quality of life in neighborhoods relative to
acquisition of properties by Rite Aid Corp., H5070 [24JN]
Dept. of Defense: include certain beneficiaries in National Mail
Order Pharmacy Program, H3466 [19MY]
------ viagra funding, H10672 [13OC]
Dept. of HHS: ensure individuals who undertake federally funded
research and development of drugs enter into pricing agreements
(H.R. 3758), E2065 [11OC]
Diseases: Medicare coverage and research funding for amyotrophic
lateral sclerosis (H.R. 2009), H1623 [26MR]
Drugs: civil liability for illegal manufacturers and distributors
of controlled substances, H7884 [16SE], H7885 [16SE]
------ exclusivity periods for medications to treat drug addiction,
H7860-H7863 [16SE], H7870 [16SE]
------ limit amount of controlled substances allowed to be brought
into the U.S. from Mexico (H.R. 3633), H6903-H6906 [3AU]
------ support existing Federal legal process for determining safety
and efficacy of using marijuana and other drugs for medicinal
purposes (H.J. Res. 117), H7719-H7726 [15SE]
Federal Employees Health Benefits Program: coverage of
abortifacients, H5719-H5722 [16JY]
------ coverage of contraceptives under any plan providing
prescription drug coverage, H5568 [15JY], H5569 [15JY], H5571
[15JY], H5677-H5684 [16JY], H5694-H5697 [16JY], H5865 [20JY],
E1346 [17JY]
------ coverage of contraceptives under any plan providing
prescription drug coverage, H9184 [29SE], H9190 [1OC], H9339
[2OC], H9914-H9919 [7OC], H9928-H9932 [7OC]
Foreign trade: limit controlled substances from Mexico (H.R. 3633),
E569 [2AP]
Medicare: coverage of outpatient prescription drugs and home
infusion drug therapy (H.R. 4753), E1956 [8OC], E1969 [8OC],
E1980 [9OC], E2101 [12OC]
------ exempt licensed pharmacists from surety bond requirements for
suppliers of durable medical equipment, H614 [25FE]
------ limit payments for drugs or biological products (H.R. 3139),
H302 [4FE]
------ reductions in prescription drug prices (H.R. 4627), H10920
[15OC], E1898 [2OC], E2060 [11OC], E2061 [11OC], E2065 [11OC]
------ reductions in prescription drug prices (H.R. 4646), H9182
[29SE], H9183 [29SE], H9195-H9201 [1OC], H9352 [5OC], E1866
[1OC], E1869 [1OC], E1893 [2OC], E2059 [11OC], E2060 [11OC]
------ treatment of prescription drugs (H.R. 4627), H9163 [28SE]
National Community Pharmacists Association: anniversary, E2252
[20OC]
Prescription Drug Price Monitoring Commission: establish (H.R.
3925), H4231 [5JN]
Schering-Plough Corp.: patent extension for certain
pharmaceuticals, E2121 [13OC]
Senior citizens: establish a program of pharmacy assistance fee for
elderly persons who have no health insurance coverage (H.R.
2681), E2060 [11OC]
Remarks in Senate
Arms Export Control Act: exempt medicines and medical equipment
from the application of sanctions, S7813 [9JY]
Contraceptives: require equitable coverage of drugs, devices, and
services under health insurance plans (S. 743), S4772 [13MY]
DEA: assessment of fines on pharmacies for record keeping
violations, S8876 [23JY]
------ assessment of fines on pharmacies for record keeping
violations (S. 2600), S12168 [9OC]
Diseases: Medicare coverage and research funding for amyotrophic
lateral sclerosis (S. 2265), S7575 [7JY]
------ prostate cancer research programs funding, S8442 [17JY]
------ tribute to cooperative initiatives between pharmaceutical
companies and Federal Government to combat infectious diseases
worldwide, S276 [2FE]
Drugs: limit amount of controlled substances allowed to be brought
into the U.S. from Mexico and Canada (S. 2242), S7260 [26JN]
------ limit amount of controlled substances allowed to be brought
into the U.S. from Mexico (H.R. 3633), S12680 [20OC], S12681
[20OC]
------ provide incentives for the development of medications to
treat drug addiction (S. 2015), S3932 [30AP]
------ rescheduling of certain drugs which pose a danger to public
safety (S. 2014), S3931 [30AP]
------ support existing Federal legal process for determining safety
and efficacy of using marijuana and other drugs for medicinal
purposes (S.J. Res. 56), S10665-S10667 [21SE], S10673 [22SE],
S10713 [22SE] support existing Federal legal process for
determining safety and efficacy of using marijuana and other
drugs for medicinal purposes (S.J. Res. 57), S10665-S10667
[21SE]
FDA: Office of Generic Drugs funding, S8120 [14JY]
------ orphan products research funding, S8099 [14JY]
------ reform testing and approval process for certain generic
drugs, S12846 [21OC]
------ require notification of recalls of drugs and devices (S.
1767), S1995 [16MR]
Federal Employees Health Benefits Program: coverage of
contraceptives under any plan providing prescription drug
coverage, S9193-S9199 [29JY]
------ coverage of contraceptives under any plan providing
prescription drug coverage, S11681 [7OC], S12135 [9OC], S12136
[9OC]
Foreign policy: exempt agricultural products, medicines, and
medical equipment from unilateral economic sanctions,
S8214-S8228 [15JY]
----- exempt agricultural products, medicines, and medical equipment
from unilateral economic sanctions except to countries
sponsoring international terrorism, S8226-S8228 [15JY]
Henney, Jane: nomination to be FDA Commissioner, S7031 [24JN]
Medicare: exempt licensed pharmacists from surety bond requirements
for suppliers of durable medical equipment (S. 1680),
S1012-S1014 [25FE]
NIH: establish National Center for Complementary and Alternative
Medicine (S. 2420), S9593 [31JY]
Tariff: anti-cancer drugs (S. 1936), S3219 [3AP]
------ anti-cancer drugs (S. 1937), S3219 [3AP]
------ anti-cancer drugs (S. 1938), S3219 [3AP]
------ anti-cancer drugs (S. 1939), S3219 [3AP]
------ anti-cancer drugs (S. 1940), S3219 [3AP]
------ anti-cancer drugs (S. 1941), S3219 [3AP]
------ anti-cancer drugs (S. 1944), S3219 [3AP]
------ anti-cancer drugs (S. 1945), S3219 [3AP]
------ anti-HIV and anti-AIDS drug production (S. 1810), S2429
[23MR]
------ HIV antiviral drug production (S. 1946), S3219 [3AP]
------ HIV antiviral drug production (S. 2399), S9560 [31JY]
------ HIV protease inhibitor production (S. 1942), S3219 [3AP]
------ HIV protease inhibitor production (S. 1943), S3219 [3AP]
Taxation: treatment of excise tax on vaccines (S. 2118), S5447
[22MY]
Women: release of study on abuse of alcohol, cigarettes, and
psychoactive prescription drugs by older women, S5658 [4JN]
Reports
Drug Pricing in the 9th Congressional District of Tennessee--Drug
Companies Profit at the Expense of Older Americans: Committee
of Government Reform and Oversight (House), E2062-E2065 [11OC]
Reports filed
Limit Amount of Controlled Substances Allowed To Be Brought Into the
U.S. From Mexico: Committee on the Judiciary (House) (H.R.
3633) (H. Rept. 105-629), H5735 [16JY]
Summaries
Medicare Coverage of Outpatient Prescription Drugs and Home Infusion
Drug Therapy (H.R. 4753), E1957 [8OC]
Tables
Federal cost of illustrative Medicare benefits package including
prescription drug and stop-loss coverage, E1981 [9OC]
Federal cost of Medicare drug coverage under alternative cost
sharing requirements with Medicaid offsets, E1981 [9OC]
Prescription drug benefit costs for SMI enrollees, E1981 [9OC]
Prescription drug price differentials, H9183 [29SE]
Texts of
H.J. Res. 117, support existing Federal legal process for
determining safety and efficacy of using marijuana and other
drugs for medicinal purposes, H7719 [15SE]
H.R. 3633, Controlled Substances Trafficking Prohibition Act, H6903
[3AU]
S. 1680, exempt licensed pharmacists from surety bond requirements
for suppliers of durable medical equipment under Medicare, S1013
[25FE]
S. 1767, Drug and Device Recall Reporting Act, S1995 [16MR]
S. 1810, tariff on anti-HIV and anti-AIDS drug production, S2429
[23MR]
S. 1936, tariff on anti-cancer drugs, S3220 [3AP]
S. 1937, tariff on anti-cancer drugs, S3220 [3AP]
S. 1938, tariff on anti-cancer drugs, S3220 [3AP]
S. 1939, tariff on anti-cancer drugs, S3220 [3AP]
S. 1940, tariff on anti-cancer drugs, S3221 [3AP]
S. 1941, tariff on anti-cancer drugs, S3221 [3AP]
S. 1942, tariff on HIV protease inhibitor production, S3221 [3AP]
S. 1943, tariff on HIV protease inhibitor production, S3221 [3AP]
S. 1944, tariff on anti-cancer drugs, S3221 [3AP]
S. 1945, tariff on anti-cancer drugs, S3221 [3AP]
S. 1946, tariff on HIV antiviral drug production, S3221 [3AP]
S. 2265, Amyotrophic Lateral Sclerosis (ALS) Research, Treatment,
and Assistance Act, S7575 [7JY]
S. 2399, tariff on HIV antiviral drug production, S9560 [31JY]